In the context of pancreatic cancer, VEE-CEA was applied for intramuscular administration of 4 × 107 to 4 × 108 IU in pancreatic cancer patients in a phase I study [150]. The gene discussed is CEACAM5; the disease is pancreatic neoplasm.